Northwest Denver church searching for $1 million in order to stay where it's at
The food pantry director at the Redeeming Love Fellowship Church says leaders were recently informed by the landowners of their intent to sell.
Red Rocks Easter Sunrise Service 2025: Everything you need to know
The owners are giving the church first crack at coming up with $1 million by June 30.
'The Lord has called us to answer the call,' said Eden Armendariz, food bank director. 'And we are answering that call.'
The non-denominational church is located at the corner of 41st Avenue and Kalamath Street and includes a food pantry, which serves 800 to 1,000 people a month.
The church also provides social services, transportation, and bilingual help.
If you'd like to donate, please call 720-328-1934.
A GoFundMe to help the church reach its goal has been established here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
9 minutes ago
- Forbes
Manual Testing Meets AI: The Future Of Quality Assurance
Ruslan Desyatnikov is Founder and CEO of QA Mentor, Inc., an independent software-testing company headquartered in New York. getty As AI technology and no-code automation tools continue to evolve, manual testing seems to be losing its edge. This perception may or may not align with reality, as multiple factors are impacting manual testing, including budget cuts driven by the tech sector slump. But as QA professionals, we must acknowledge the realities outlined in the latest World Quality Report, which highlights the forces shaping the future of manual testing. Here's a closer look at what's happening: • Automation is outpacing traditional testing. Manual effort was identified by over half of the respondents as a key factor reduced by automation, resulting in lower operating costs, fewer defects and improvement in user experiences. • Manual testing is on life support? Only 10% of respondents said that manual testing is still prevalent due to specific application architectures. • GenAI is taking over. Manual effort can be minimized as GenAI in quality engineering enhances test data creation, test case generation, automation, defect analysis and regression efficiency, enabling teams to execute thorough regression cycles quickly. • SDET is a hot commodity. Almost 30% of respondents highlighted increased demand for software development engineers in test (SDET) who possess coding skills in addition to traditional test experience. • Hyper automation is the new standard. Manual testing is at risk of obsolescence as hyper automation transforms manufacturing by reducing routine tasks, speeding up production and maintaining high-quality standards. The Manual Tester's Renaissance: How Human Expertise Is Evolving For AI Analyzing this data, it seems like manual testing is losing ground. But if you look deeper, none of the five bullet points make a convincing case that the curtain is about to fall on manual testing. The third item is a cause for concern, but it contradicts what we're seeing at our company. As the founder of QA Mentor, a global software testing and quality assurance services company, I can confirm that despite the rise of AI, manual testers remain in high demand. In fact, 89% of our client requests still require their expertise. The Case For Human-Driven QA Our numbers are actually reinforced by the World Quality Report. The publication revealed that only 19% of respondents believe developers can handle all forms of testing, rendering separate testing teams unnecessary. This underscores the irreplaceable value of human judgment in maintaining quality and tackling the complex, nuanced issues that automation just can't manage. What the report correctly highlights is that the role of manual testers is evolving. Humans are crucial in validating AI-generated outputs. This is why the authors advocate for a hybrid approach that combines manual expertise with automation, and where SMEs review and refine AI-generated test cases. They also call for establishing a robust feedback loop for streamlining the process to strike the balance between efficiency, accuracy and quality control. Back To The Dot-Com: How Budget Cuts Are Reviving QA's Struggles Along with AI driving the change, some QA specialists argue that manual testing is facing the chopping block due to shift-left practices, which emphasize integrating QA from the outset. As an industry insider, I believe the challenges facing manual QAs and the QA sector have less to do with either; the shift-left approach has been with us for years. The challenges are more closely linked to the ongoing downturn in the tech industry. In 2023, 1,193 tech companies executed layoffs, resulting in the loss of 264,220 jobs, a pattern that persisted into 2024. Last year, more than 500 tech firms collectively laid off about 150,000 employees. While this may sound alarming, it's actually nothing we haven't seen. We're witnessing a modern-day version of what transpired 25 years ago. During the dot-com bubble, organizations trimmed costs by scaling back dedicated QA functions, while tech companies prioritized speed over quality assurance in their race for growth. As QA was overlooked, it left products vulnerable to failures, ultimately contributing to the collapse of many promising ventures. Unfortunately, history appears to be repeating itself, as budget cuts often lead IT departments to target QA as the first area for layoffs. QA Failures That Hurt Big Names is a classic cautionary tale from the dot-com bubble, illustrating how hype and rapid growth can't compensate for poor execution. Despite raising $135 million, the site was plagued by slow load times, browser incompatibility and backend failures. Its flashy, graphics-heavy interface alienated dial-up users, while technical instability and fulfillment issues eroded trust. collapse illustrates how ignoring user experience and QA can derail even the most well-funded ventures. Here are a few more stories of companies that highlight the importance of QA: • Equifax: In 2017, Equifax, one of the major credit reporting agencies, experienced a data breach that exposed the sensitive information of 147 million individuals. The incident was linked to unpatched software vulnerabilities and shortcomings in security processes, ultimately resulting in regulatory penalties and reputational impact. • GitLab: This cloud-based DevOps platform experienced an incident in which thousands of user projects were lost due to a system misconfiguration and insufficient backup procedures, drawing attention to gaps in quality assurance and disaster recovery planning. • British Airways: In 2017 and 2019, system failures led to flight disruptions, and a data breach in 2018 resulted in significant financial penalties and operational impact. • Southwest Airlines: During the 2022 holiday season, Southwest Airlines canceled over 16,000 flights due in part to outdated scheduling software, resulting in widespread travel disruptions and substantial financial losses. • Rogers: In 2022, Rogers Communications experienced a nationwide outage affecting over 12 million customers after a configuration error during a system update. The disruption impacted mobile and internet services, including access to emergency services. Conclusion AI and automation are flipping testing on its head, but manual testers aren't out of the game yet. The future lies in a powerful combination of human instincts and AI speed. If companies cut QA for the sake of growth, they're flirting with disaster, and history's brutal lessons prove it. Only the right balance will ensure that quality survives. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Business Wire
an hour ago
- Business Wire
Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via telephone from within the United States and Canada, dial +1 (833) 470-1428. From outside the United States and Canada, dial +1 (404) 975-4839. The access code for the call will be 015103. Replays of the call will be made available via telephone and webcast. A replay of the webcast will be posted on approximately one hour after the completion of the call and will remain available for one year. The telephonic replay will also be available approximately one hour after the completion of the call and will remain available for 7 days. To access the telephonic replay from within the United States and Canada, dial +1 (866) 813-9403. From outside the United States, dial +1 (929) 458-6194. The access code for the replay is 676245. Please check the website for updates regarding the timing of the live webcasts and for replay information. About Cencora Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Cencora partners with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on Cencora for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Cencora's 51,000+ worldwide team members contribute to positive health outcomes through the power of Cencora's purpose: Cencora is united in its responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue. Learn more at
Business Wire
an hour ago
- Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 175,000 shares of the company's common stock to one new employee (the 'Inducement Grant') on July 1, 2025 (the 'Grant Date'). The Inducement Grant has been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the 'Plan') but remains subject to the terms and conditions of such Plan. The Inducement Grant was granted as an inducement material to the individual entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price per share that is equal to the closing price of Viridian's common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to the employee's continued employment with Viridian through the applicable vesting dates. About Viridian Therapeutics Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit Follow Viridian on LinkedIn and X.
